Gilead Sciences (NQ:GILD)

U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

December 21, 2023

It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ ↗

December 21, 2023

Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million,

Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? ↗

December 21, 2023

Via Benzinga

(GILD) - Analyzing Gilead Sciences's Short Interest ↗

December 18, 2023

Via Benzinga

A Look Into Gilead Sciences Inc's Price Over Earnings ↗

December 07, 2023

Via Benzinga

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today ↗

December 06, 2023

Via Benzinga

Why Is Hookipa Pharma (HOOK) Stock Up 81% Today? ↗

December 21, 2023

Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK.

RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola ↗

December 20, 2023

RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc (NASDAQ: GILD) Veklury...

Via Benzinga

QQQ And QQQM ETFs Top Gainers And Laggards Of 2023 ↗

December 20, 2023

This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference...

Via Talk Markets

Topics ETFs

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 19, 2023

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...

Via Benzinga

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗

December 19, 2023

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the

Via Benzinga

Why Is Compugen (CGEN) Stock Up 189% Today? ↗

December 19, 2023

Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

December 19, 2023

Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy. ↗

December 16, 2023

Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.

Via The Motley Fool

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗

December 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

Investors should take notice ofGILEAD SCIENCES INC (NASDAQ:GILD)—it offers a great deal for the fundamentals it presents.

NASDAQ:GILD is probably undervalued for the fundamentals it is displaying. ↗

December 12, 2023

Via Chartmill

A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street ↗

December 12, 2023

There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.

Via The Motley Fool

Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

December 11, 2023

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

December 11, 2023

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

December 11, 2023

Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions ↗

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 11, 2023

Via Benzinga

December 11, 2023

Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion...

Via Benzinga

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

December 11, 2023

Regulators are already on the case, and their findings will have financial impacts.

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗

December 10, 2023

Via The Motley Fool

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

Via MarketBeat

Topics ETFs

A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene

December 07, 2023

Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

November 30, 2023